----item----
version: 1
id: {DE29CD99-7F02-49E4-9F9E-47CAFA05EA3D}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/08/27/Taro generic Doxil approval bring Sun shine
parent: {4497F46D-3201-4913-B491-A39A212D961C}
name: Taro generic Doxil approval bring Sun shine
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: e2648efa-a168-4f69-b1e3-5f51e2cc6583

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 45

Taro, generic Doxil approval bring Sun shine 
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 43

Taro generic Doxil approval bring Sun shine
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1619

<p>Sun Pharmaceutical Industries rose on Indian bourses after its Israel-based subsidiary, Taro Pharmaceutical Industries, reported a strong quarter and the US FDA approved the firm&rsquo;s generic version of J&J&rsquo;s anticancer, Doxil (doxorubicin hydrochloride liposome injection) to tackle shortages of the product. </p><p>Sun&rsquo;s shares rose by more than 4% to close at Rs747.30 ($14) on the Bombay Stock Exchange on 5 February.</p><p>While Taro reported net sales of $185.7 million (+25.4%) and net profits of $88.8 million (+42%) for the quarter ended December 2012, analysts were also upbeat about the prospects of the first generic approval for Sun&rsquo;s doxorubicin injection. &ldquo;We expect Sun to perhaps even better the current run rate for doxorubicin, going forward,&rdquo; an analyst with an Indian brokerage told <i>Scrip</i>, with some reports projecting annual sales of close to $80 million from the product till more generic competition arrives. The FDA is currently using a priority review system to expedite the review of generic applications to help alleviate shortages.</p><p>In February 2012, the FDA had cleared the temporary &lsquo;controlled&rsquo; importation of Sun&rsquo;s Lipodox, an alternative to Doxil. The agency said that once supplies of Sun&rsquo;s generic version are sufficient to meet projected demand, it expects to stop exercising enforcement discretion for any unapproved doxorubicin HCl liposomal product.</p><p>Doxil has been in short supply following manufacturing issues at Ben Venue Laboratories Inc, an Ohio-based CMO and an arm of Boehringer Ingelheim. </p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 326

<p>Sun Pharmaceutical Industries rose on Indian bourses after its Israel-based subsidiary, Taro Pharmaceutical Industries, reported a strong quarter and the US FDA approved the firm&rsquo;s generic version of J&J&rsquo;s anticancer, Doxil (doxorubicin hydrochloride liposome injection) to tackle shortages of the product. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 43

Taro generic Doxil approval bring Sun shine
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150827T210000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150827T210000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150827T210000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC020315
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 45

Taro, generic Doxil approval bring Sun shine 
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

200000531
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{FD7E3A1B-CD6C-4EA9-909E-043A9042A71F}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

339680
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T041528Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

e2648efa-a168-4f69-b1e3-5f51e2cc6583
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T041528Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
